|
| 37541199 | Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. | Cell | 2023 |
| 36446254 | Targeting NaPi2b in ovarian cancer. | Cancer Treat Rev | 2023 |
| 37862791 | Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100. | | 2023 |
| 36718018 | Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer. | | 2023 |
| 36905875 | Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors. | Gynecol Oncol | 2023 |
| 36898292 | Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. | | 2023 |
| 36707610 | LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. | Sci Rep | 2023 |
| 37001446 | DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. | | 2023 |
| 37100807 | Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. | Nat Commun | 2023 |
| 34906376 | Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. | Gynecol Oncol | 2022 |
| 36244829 | A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial. | Gynecologic Oncology | 2022 |
| 36344654 | A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. | International Journal of Clinical Oncology | 2022 |
| 36077609 | Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study. | Cancers (Basel) | 2022 |
| 35931981 | DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer. | BMC Bioinformatics | 2022 |
| 34224438 | Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. | Applied Immunohistochemistry and Molecular Morphology | 2022 |
| 35280818 | The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways. | Front Oncol | 2022 |
| 34729846 | Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. | Head Neck | 2022 |
| 34363762 | Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. | Lancet Oncology, The | 2021 |
| 34243976 | Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. | Gynecol Oncol | 2021 |
| 33530952 | Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. | BMC Cancer | 2021 |
| 33622671 | Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 33888338 | Understanding the effect of mechanical forces on ovarian cancer progression. | Gynecol Oncol | 2021 |
| 33729494 | Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. | J Natl Cancer Inst | 2021 |
| 33667670 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. | Ann Oncol | 2021 |
| 33712274 | Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). | Gynecologic Oncology | 2021 |
| 33917869 | SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. | Cancers (Basel) | 2021 |
| 35028612 | Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. | Cell Rep Med | 2021 |
| 34820113 | Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology. | Journal of Tissue Engineering | 2021 |
| 34645978 | A highly annotated database of genes associated with platinum resistance in cancer. | Oncogene | 2021 |
| 32839025 | Corrigendum to 'Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer' [Gynecologic Oncology 157 (2020) 765-774]. | Gynecologic Oncology | 2020 |
| 32081463 | Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. | Gynecologic Oncology | 2020 |
| 32265057 | Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. | Gynecologic Oncology | 2020 |
| 32192732 | Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer. | Gynecologic Oncology | 2020 |
| 32313567 | Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. | Ther Adv Med Oncol | 2020 |
| 31843273 | Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. | Gynecologic Oncology | 2020 |
| 32303677 | Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. | Nature Communications | 2020 |
| 31831561 | A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. | Clin Cancer Res | 2020 |
| 31714586 | Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. | Int J Cancer | 2020 |
| 31871106 | The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. | Cancer Epidemiol Biomarkers Prev | 2020 |
| 31870556 | EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. | Gynecol Oncol | 2020 |
| 31613330 | Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. | Am J Clin Pathol | 2020 |
| 32213921 | Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment. | Cancers | 2020 |
| 31924334 | Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). | Gynecologic Oncology | 2020 |
| 31919136 | Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. | Clin Cancer Res | 2020 |
| 32885014 | Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 10053 | Gynecologic Oncology Reports | 2020 |
| 32534811 | Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. | Gynecologic Oncology | 2020 |
| 32816895 | Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). | Clin Cancer Res | 2020 |
| 32747365 | Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma. | Cancer Res | 2020 |
| 32847980 | Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). | Molecular Cancer Therapeutics | 2020 |
| 30827726 | GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. | Gynecol Oncol | 2019 |